648 A pilot study to evaluate the combination of zimberelimab, domvanalimab and etrumadenant in patients with previously treated non-small cell lung cancer (NSCLC)
Anjali Rohatgi(Washington University in St. Louis), Daniel Morgensztern(Barnes-Jewish Hospital), Ningying Wu(Washington University in St. Louis), Ramaswamy Govindan(Washington University in St. Louis), Siddhartha Devarakonda(Swedish Medical Center), Haobin Chen(Washington University in St. Louis), Gina M Vellequette(Washington University in St. Louis), Brett H. Herzog(Washington University in St. Louis), Waqar N Saiama(Washington University in St. Louis), Maria Q. Baggstrom(Washington University in St. Louis)
Cited by 0
Related Papers
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
|Nature Genetics|2016|1.3k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k